IL1B and Wiskott-Aldrich syndrome: Interestingly, type I IFNs are able to inhibit IL-1β secretion even in the absence of WASp, raising the possibility that type I IFN therapy is useful for pathological states related to overt inflammasome activation in WAS patients, as well as for enhancing protective immunity against pathogens to which patients are particularly susceptible in natura, such as herpes viruses.